Fund Holdings — JOHNSON & JOHNSON

Total Portfolio Value:
$400.67M
Total Bought:
$97.83M
Total Sold:
$4.05B
Net Transaction:
-$3.95B
Securities
▲▼
SharesValue
Q1 2024
▲▼
Q2 2024
▲▼
Change
▲▼
Q1 2024
▲▼
Q2 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Protagonist Therapeutics Inc.2,449,1832,449,1830$70.85M$84.86M21.18%+$14.01M
Rapport Therapeutics, Inc.(RAPP)02,498,051+2,498,051$0$58.10M14.50%+$58.10M
CVRx, Inc.(CVRX)4,103,4304,103,4300$74.72M$49.20M12.28%-$25.52M
Legend Biotech CorporationADS(LEGN)814,586814,5860$45.69M$36.08M9.00%-$9.61M
Contineum Therapeutics, Inc.CL A(CTNM)01,979,173+1,979,173$0$34.85M8.70%+$34.85M
Nanobiotix S.A.ADS(NBTX)5,623,8165,623,8160$36.55M$28.12M7.02%-$8.44M
MeiraGTx Holdings plc(MGTX)6,641,0646,641,0640$40.31M$27.96M6.98%-$12.35M
PROCEPT BioRobotics Corporation(PRCT)357,939357,9390$17.69M$21.87M5.46%+$4.18M
Neumora Therapeutics, Inc.(NMRA)1,849,4451,849,4450$25.43M$18.18M4.54%-$7.25M
Xencor, Inc.(XNCR)748,062748,0620$16.55M$14.16M3.53%-$2.39M
Fate Therapeutics, Inc.(FATE)3,379,0643,379,0640$24.80M$11.08M2.77%-$13.72M
Arrowhead Pharmaceuticals, Inc.(ARWR)247,598247,5980$7.08M$6.44M1.61%-$646.2K
Rallybio Corporation(RLYB)03,636,363+3,636,363$0$4.87M1.22%+$4.87M
Nano-X Imaging Ltd.
ORD SHS
158,852158,8520$1.55M$1.17M0.29%-$386.0K
Vor Biopharma Inc.(VOR)1,074,6581,074,6580$2.55M$1.07M0.27%-$1.47M
Aldeyra Therapeutics, Inc.(ALDX)299,669299,6690$979.9K$991.9K0.25%+$12.0K
Tessera Defense and Homeland Security Inc.(HLSQ)1,923,2011,923,2010$865.4K$646.4K0.16%-$219.1K
Standard BioTools Inc.(LAB)311,967311,9670$845.4K$552.2K0.14%-$293.2K
Adicet Bio, Inc.364,472364,4720$856.5K$441.0K0.11%-$415.5K
Senseonics Holdings, Inc.(SENS)54,62154,6210$29.0K$21.8K0.01%-$7.2K
Clearside Biomedical, Inc.169,6290-169,629$259.5K$0—-$259.5K
Fusion Pharmaceuticals Inc.3,670,5160-3,670,516$78.26M$0—-$78.26M
Tracon Pharmaceuticals, Inc.84,0030-84,003$36.1K$0—-$36.1K
Shockwave Medical, Inc.166,8120-166,812$54.32M$0—-$54.32M
Kenvue Inc.(KVUE)182,329,5500-182,329,550$3.91B$0—-$3.91B
Page 1 of 1
JOHNSON & JOHNSON — 13F Holdings — Q2 2024 | TickerTrail